BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasiri-Ansari N, Androutsakos T, Flessa CM, Kyrou I, Siasos G, Randeva HS, Kassi E, Papavassiliou AG. Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. Cells 2022;11:2511. [PMID: 36010588 DOI: 10.3390/cells11162511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Nasiri-Ansari N, Kassi E. Editorial: Special issue: Non-alcoholic fatty liver disease: From molecular basis to therapeutic advances. Metabol Open 2023;17:100229. [PMID: 36686606 DOI: 10.1016/j.metop.2023.100229] [Reference Citation Analysis]
2 Li J, Zhang X, Tian J, Li J, Li X, Wu S, Liu Y, Han J, Ye F. CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation Dysfunction Associated with Nonalcoholic Fatty Liver Disease. Pharmaceuticals (Basel) 2023;16:106. [PMID: 36678603 DOI: 10.3390/ph16010106] [Reference Citation Analysis]
3 Pei J, Palanisamy CP, Alugoju P, Anthikapalli NVA, Natarajan PM, Umapathy VR, Swamikannu B, Jayaraman S, Rajagopal P, Poompradub S. A Comprehensive Review on Bio-Based Materials for Chronic Diabetic Wounds. Molecules 2023;28. [PMID: 36677658 DOI: 10.3390/molecules28020604] [Reference Citation Analysis]
4 Krznarić J, Vince A. The Role of Non-Alcoholic Fatty Liver Disease in Infections. Life (Basel) 2022;12. [PMID: 36556417 DOI: 10.3390/life12122052] [Reference Citation Analysis]
5 Albadawy R, Hasanin AH, Agwa SHA, Hamady S, Aboul-Ela YM, Raafat MH, Kamar SS, Othman M, Yahia YA, Matboli M. Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death. Int J Mol Sci 2022;23:10148. [PMID: 36077546 DOI: 10.3390/ijms231710148] [Reference Citation Analysis]